title: Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
abstract: This study determined the disposition of irinotecan hydrochloride trihydrate (CPT-11) after i.v. infusion of 125 mg/m(2) (100 microCi) [(14)C]CPT-11 in eight patients with solid tumors. Mean +/- S.D. recovery of radioactivity in urine and feces was 95.8 +/- 2.7% (range 92.2-100.3%, n = 7) of dose. Radioactivity in blood, plasma, urine, and feces was determined for at least 168 h after dosing. Fecal excretion accounted for 63.7 +/- 6.8 (range 54.2-74.9%, n = 7) of dose, whereas urinary excretion accounted for 32.1 +/- 6.9% (range 21.7-43.8%; n = 7) of dose. One patient with a biliary T-tube excreted 30.1% of dose in bile, 14.2% in feces, and 48.2% in urine. Quantitative radiometric HPLC revealed that CPT-11 was the major excretion product in urine, bile, and feces. Aminopentane carboxylic acid (APC) and SN-38 glucuronide (SN-38G) were the most significant metabolites in urine and bile, whereas SN-38 and NPC, a primary amine metabolite, were relatively minor excretion products. SN-38 and APC were the most significant metabolites in feces. The relatively higher amount of SN-38 in feces compared with bile is presumably due to hydrolysis of SN-38G to SN-38 by enteric bacterial beta-glucuronidases. There was close correspondence between quantitative fluorescence HPLC and mass balance findings. CPT-11 was the major circulating component in plasma (55% of the mean radiochemical area under the curve), and CPT-11, SN-38, SN-38G, and APC accounted for 93% of the mean radiochemical AUC. These results show that the parent drug and its three major metabolites account for virtually all CPT-11 disposition, with fecal excretion representing the major elimination pathway.
authors.affiliation: Pharmacia & Upjohn Company, Kalamazoo, Michigan 49007, USA. john.g,slatter@am.pnu.com
authors.forename: J G
authors.initials: JG
authors.lastname: Slatter
authors.forename: L J
authors.initials: LJ
authors.lastname: Schaaf
authors.forename: J P
authors.initials: JP
authors.lastname: Sams
authors.forename: K L
authors.initials: KL
authors.lastname: Feenstra
authors.forename: M G
authors.initials: MG
authors.lastname: Johnson
authors.forename: P A
authors.initials: PA
authors.lastname: Bombardt
authors.forename: K S
authors.initials: KS
authors.lastname: Cathcart
authors.forename: M T
authors.initials: MT
authors.lastname: Verburg
authors.forename: L K
authors.initials: LK
authors.lastname: Pearson
authors.forename: L D
authors.initials: LD
authors.lastname: Compton
authors.forename: L L
authors.initials: LL
authors.lastname: Miller
authors.forename: D S
authors.initials: DS
authors.lastname: Baker
authors.forename: C V
authors.initials: CV
authors.lastname: Pesheck
authors.forename: R S
authors.initials: RS
authors.lastname: Lord
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001646:Bile / Q000737:chemistry / Q000378:metabolism; D001711:Biotransformation; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D005243:Feces / Q000737:chemistry; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D000077146:Irinotecan; D008297:Male; D013058:Mass Spectrometry; D008875:Middle Aged; D009369:Neoplasms / Q000378:metabolism
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin